This deal with Elly Lilly is oncology.
https://endpts.com/eli-lillys-van-naarden-puts-up-380m-in-cash-to-land-a-major-new-oncology-deal/
FTO is shaping up to be bigger ~ 15% of all tumors …
- $380M upfront ( $300n cash + $80 equity )
- $1.3 billion in potential milestones
- co-development and co-commercialization rights to their BRM selective program — which uses protein degradation and enzymatic inhibition — directed against BRG1 mutations. Those mutations are aligned along 5% of all tumors and 10% of NSCLC.
Industry news, page-421
-
- There are more pages in this discussion • 1,437 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
-0.020(1.40%) |
Mkt cap ! $240.2M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.46 | $1.38 | $107.6K | 75.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1675 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 799 | 2 |
View Market Depth
| Last trade - 14.56pm 08/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |